GET DAILY SIGNALSWhy Is Accendra Health (ACH) Stock Down -18.71% Today?
Key Takeaways
- Shares of ACH fell roughly 18.7% Monday, trading near $0.165 after closing the prior session at $0.2031, extending a steep multi-session decline.
- The primary catalyst is continued fallout from a disappointing third-quarter earnings report and a sharp downward revision to full-year guidance.
- Secondary pressure comes from New York Stock Exchange continued-listing notices tied to the company's sub-$1 share price, market capitalization, and negative stockholders' equity.
- Analyst downgrades and price-target cuts have reinforced bearish sentiment around the turnaround story.
- The stock is breaking to new 52-week lows, with the move reflecting company-specific distress rather than a broader market selloff.
- Traders are watching for the company's NYSE compliance plan, liquidity updates, and any news on a potential reverse stock split.
- For additional detail, explore Accendra Health's Price Targets, Earnings, and Forecast pages.
- To see how automated strategies are positioned across the market, explore Trending AI Robots.
Opening Summary
ACH, the ticker for Accendra Health, Inc., is a Richmond, Virginia-based provider of home-based healthcare products and services. Formerly known as Owens & Minor, the company operates through its Apria and Byram brands, serving patients in diabetes, sleep, respiratory, wound, ostomy, urology, and incontinence care. On Monday, the shares extended a punishing decline, falling about 18.7% to roughly $0.165 in morning trading, down from a prior close of $0.2031. The move follows last week's weaker-than-expected third-quarter results, a cut to full-year guidance, and mounting concerns about the company's compliance with NYSE listing standards.
Disappointing Q3 Results and Cut Guidance
The heaviest weight on the stock is the company's third-quarter earnings report, released after the market closed on November 5. Accendra Health posted a non-GAAP loss of $0.23 per share, well below the consensus estimate, while revenue of approximately $601.8 million also missed expectations and declined from $697.3 million a year earlier. Adjusted EBITDA fell to $47.8 million from $92.2 million in the prior-year period. Management acknowledged that near-term profit-improvement efforts "did not yield the expected results," citing weakness in continuous glucose monitoring, respiratory, and wound categories that offset growth in sleep and diabetes supply lines.
Compounding the earnings miss, the company cut its outlook. Accendra Health said full-year revenue would come in at the low end of its prior $2.45 billion to $2.55 billion range and warned that adjusted EBITDA could be as much as 30% below the $310 million midpoint of its previous guidance. The combination of a bottom-line miss, a revenue shortfall, and reduced forward expectations triggered an earnings-driven selloff that has continued into the new trading week.
NYSE Listing Pressure and Delisting Risk
A second structural overhang is the company's compliance status with the New York Stock Exchange. In October, Accendra Health disclosed two continued-listing notices. The first, received October 6, cited a 30-trading-day average closing price below $1.00 under the NYSE's minimum-price standard. A second notice, received October 27, flagged that the company's 30-day average market capitalization and stockholders' equity had fallen below the exchange's $50 million thresholds. The equity shortfall is substantial, as the company's book value is deeply negative against roughly $1.8 billion of total debt. While these notices do not trigger immediate delisting, they give management a defined window to submit a compliance plan and have raised questions about the path to regaining compliance, including the potential use of a reverse stock split.
Analyst Reaction
Wall Street's response has been decidedly cautious. In the wake of the results, at least one major firm lowered its price target on ACH, trimming it from $0.50 to $0.25 while maintaining a neutral stance. The consensus rating across the handful of analysts covering the stock sits at Hold, with no Buy ratings, and price targets have been cut repeatedly through 2026 as the turnaround has stalled. This steadily shrinking valuation floor has added to the selling pressure and left few near-term catalysts to support a rebound.
Market Context and Trading Activity
The decline in ACH is largely company-specific. The stock has now fallen more than 90% over the trailing 52 weeks, breaking below prior support and carving out new lows near $0.165, well under both its 50-day and 200-day moving averages. Trading volume has remained elevated relative to historical norms as investors reposition around the guidance reset and the listing-compliance headlines. The move does not appear to reflect broad weakness in healthcare or the major equity indices; rather, it is a continuation of a distressed micro-cap selloff driven by deteriorating fundamentals, heavy leverage, and regulatory listing pressure.
What Comes Next for Accendra Health
Looking ahead, the key milestones for ACH center on its NYSE compliance plan, which the company must submit within 45 days of the October 27 notice, and on whether management can stabilize collections and cash flow under new leadership. Investors will also monitor whether a reverse stock split is proposed at the company's next annual meeting as a means of curing the minimum-price deficiency. Risks remain significant: negative stockholders' equity, persistent net losses, and a large debt load leave limited room for error, while any failure to regain compliance could accelerate downside for shareholders. The company has said it expects to maintain adequate liquidity for the foreseeable future, but execution on its turnaround will be the decisive factor.
Trending AI Robots
Tickeron's Trending AI Robots page highlights a curated selection of automated trading bots, drawn from a broader library of hundreds of AI-driven strategies that cover thousands of tickers. Only the strongest performers under current market conditions are featured in this section. The bots vary by strategy, timeframe, performance metrics, and the symbols they trade, giving traders a range of approaches to review. Explore the Trending AI Robots page to see which automated strategies are currently leading the market.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
ACH's RSI Oscillator sits in oversold zone for 1 day
It is expected that a price bounce should occur soon.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
The Moving Average Convergence Divergence (MACD) for ACH just turned positive on October 06, 2026. Looking at past instances where ACH's MACD turned positive, the stock continued to rise in 35 of 47 cases over the following month. The odds of a continued upward trend are 74%.
Following a +11.25% 3-day Advance, the price is estimated to grow further. Considering data from situations where ACH advanced for three days, in 220 of 288 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 06, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ACH as a result. In 74 of 86 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 86%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ACH declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
The Aroon Indicator for ACH entered a downward trend on November 03, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 5 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 21 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-0.028) is normal, around the industry mean (14.423). P/E Ratio (-0.051) is within average values for comparable stocks, (11.188). Projected Growth (PEG Ratio) (0.090) is also within normal values, averaging (2.016). Dividend Yield (0.013) settles around the average of (0.134) among similar stocks. P/S Ratio (0.031) is also within normal values, averaging (4.260).
The Tickeron Seasonality Score of 65 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 97 (best 1 - 100 worst), indicating slightly worse than average price growth. ACH’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ACH’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 73, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of alumina, primary aluminum and aluminum fabricated products
Industry MedicalDistributors
Advertisement